Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer

← catalyst calendar

NCT02152631 · results posted

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
453actual
Sites
231
Countries
Argentina, Austria, Brazil +18

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2014-10-03actualWhen the study began enrolling
Primary completion2017-09-15actualThe date the last participant is measured for the primary outcome — the readout window
Study completionDec 2026estimatedThe whole study's end, after follow-up
First posted2014-06-02estimatedWhen this record first appeared on the registry
Results posted2018-12-12actualWhen the sponsor posted results to the registry
Record updated2026-02-06actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Non Small Cell Lung Cancer

Interventions

  • Drug: Abemaciclib — also filed as LY2835219
  • Drug: Erlotinib

Primary outcome

what the primary-completion date above is the date OF
Overall Survival (OS)
measured From Randomization Date to Date of Death from Any Cause (Up to 32 Months)

Posted documents

hosted by the registry — we link, never re-serve
Study Protocol: Protocolposted 2014-05-13 · 847 KB · Prot_001.pdf
Study Protocol: Protocol (e)posted 2016-12-20 · 1.0 MB · Prot_002.pdf
Statistical Analysis Planposted 2017-10-02 · 827 KB · SAP_000.pdf

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed